Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Hint of non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.
Project details
- Project no.
- A21-77
- Commission
- Commission awarded on 31.05.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Addendum
Enzalutamide (prostate cancer) - Addendum to Commission A21-77
Status: Commission completed